- Immunohistochemical Expression and Clinical Significance of Suggested Stem Cell Markers in Hepatocellular Carcinoma
-
Jong Jin Sung, Sang Jae Noh, Jun Sang Bae, Ho Sung Park, Kyu Yun Jang, Myoung Ja Chung, Woo Sung Moon
-
J Pathol Transl Med. 2016;50(1):52-57. Published online November 18, 2015
-
DOI: https://doi.org/10.4132/jptm.2015.10.09
-
-
9,939
View
-
77
Download
-
21
Web of Science
-
18
Crossref
-
 Abstract
 PDF
- Background
Increasing evidence has shown that tumor initiation and growth are nourished by a small subpopulation of cancer stem cells (CSCs) within the tumor mass. CSCs are posited to be responsible for tumor maintenance, growth, distant metastasis, and relapse after curative operation. We examined the expression of CSC markers in paraffin-embedded tissue sections of hepatocellular carcinoma (HCC) and correlated the results with clinicopathologic characteristics. Methods: Immunohistochemical staining for the markers believed to be expressed in the CSCs, including epithelial cell adhesion molecule (EpCAM), keratin 19 (K19), CD133, and CD56, was performed in 82 HCC specimens. Results: EpCAM expression was observed in 56% of the HCCs (46/82) and K19 in 6% (5/82). EpCAM expression in HCC significantly correlated with elevated α-fetoprotein level, microvessel invasion of tumor cells, and high histologic grade. In addition, Ep- CAM expression significantly correlated with K19 expression. The overall survival and relapsefree survival rates in patients with EpCAM-expressing HCC were relatively lower than those in patients with EpCAM-negative HCC. All but two of the 82 HCCs were negative for CD133 and CD56, respectively. Conclusions: Our results suggest that HCCs expressing EpCAM are associated with unfavorable prognostic factors and have a more aggressive clinical course than those not expressing EpCAM. Further, the expression of either CD133 or CD56 in paraffin-embedded HCC tissues appears to be rare.
-
Citations
Citations to this article as recorded by  - Spatial immune scoring system predicts hepatocellular carcinoma recurrence
Gengjie Jia, Peiqi He, Tianli Dai, Denise Goh, Jiabei Wang, Mengyuan Sun, Felicia Wee, Fuling Li, Jeffrey Chun Tatt Lim, Shuxia Hao, Yao Liu, Tony Kiat Hon Lim, Nye-Thane Ngo, Qingping Tao, Wei Wang, Ahitsham Umar, Björn Nashan, Yongchang Zhang, Chen Ding
Nature.2025; 640(8060): 1031. CrossRef - Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma in 2025
Karan Kumar, Vivek A. Saraswat
Journal of Clinical and Experimental Hepatology.2025; 15(5): 102547. CrossRef - Recent Progress in Systemic Therapy for Advanced Hepatocellular Carcinoma
Narayanan Sadagopan, Aiwu Ruth He
International Journal of Molecular Sciences.2024; 25(2): 1259. CrossRef - Diagnostic value of expressions of cancer stem cell markers for adverse outcomes of hepatocellular carcinoma and their associations with prognosis: A Bayesian network meta‑analysis
Zhengrong Ou, Shoushuo Fu, Jian Yi, Jingxuan Huang, Weidong Zhu
Oncology Letters.2024;[Epub] CrossRef - Clinicopathological and prognostic value of epithelial cell adhesion molecule in solid tumours: a meta-analysis
Peiwen Ding, Panyu Chen, Jiqi Ouyang, Qiang Li, Shijie Li
Frontiers in Oncology.2023;[Epub] CrossRef - PD-L1 Downregulation and DNA Methylation Inhibition for Molecular Therapy against Cancer Stem Cells in Hepatocellular Carcinoma
Caecilia Sukowati, Loraine Kay D. Cabral, Beatrice Anfuso, Francesco Dituri, Roberto Negro, Gianluigi Giannelli, Claudio Tiribelli
International Journal of Molecular Sciences.2023; 24(17): 13357. CrossRef - EpCAM, Ki67, and ESM1 Predict Hepatocellular Carcinoma Recurrence After Liver Transplantation
Aiat Shaban Hemida, Doha Maher Taie, Moshira Mohamed Abd El-Wahed, Mohammed Ibrahim Shabaan, Mona Saeed Tantawy, Nermine Ahmed Ehsan
Applied Immunohistochemistry & Molecular Morphology.2023; 31(9): 596. CrossRef - The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers
Izabela Zarębska, Arkadiusz Gzil, Justyna Durślewicz, Damian Jaworski, Paulina Antosik, Navid Ahmadi, Marta Smolińska-Świtała, Dariusz Grzanka, Łukasz Szylberg
Clinics and Research in Hepatology and Gastroenterology.2021; 45(3): 101664. CrossRef - Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma
Zhouhong Ge, Jean C.A. Helmijr, Maurice P.H.M. Jansen, Patrick P.C. Boor, Lisanne Noordam, Maikel Peppelenbosch, Jaap Kwekkeboom, Jaco Kraan, Dave Sprengers
Translational Oncology.2021; 14(7): 101073. CrossRef - Hepatocellular Carcinoma Score and Subclassification Into Aggressive Subtypes Using Immunohistochemical Expression of p53, β-Catenin, CD133, and Ki-67
Asmaa G. Abdou, Nanis S. Holah, Dina S. Elazab, Walaa G. El-Gendy, Mohammed T. Badr, Dalia R. Al-Sharaky
Applied Immunohistochemistry & Molecular Morphology.2021; 29(1): 20. CrossRef - The prognostic significance of neuroendocrine markers and somatostatin receptor 2 in hepatocellular carcinoma
Keigo Murakami, Hiroyuki Kumata, Shigehito Miyagi, Takashi Kamei, Hironobu Sasano
Pathology International.2021; 71(10): 682. CrossRef - Predictors of recurrence and survival of hepatocellular carcinoma: A prospective study including transient elastography and cancer stem cell markers
Hend Ibrahim Shousha, Rabab Fouad, Tamer Mahmoud Elbaz, Dina Sabry, Mohamed Mahmoud Nabeel, Ahmed Hosni Abdelmaksoud, Aisha Mahmoud Elsharkawy, Zeinab Abdellatif Soliman, Ghada Habib, Ashraf Omar Abdelaziz
Arab Journal of Gastroenterology.2020; 21(2): 95. CrossRef - Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma
Ya Li, Qiuju Han, Huajun Zhao, Quanjuan Guo, Jian Zhang
Frontiers in Pharmacology.2020;[Epub] CrossRef - The mRNA Distribution of Cancer Stem Cell Marker CD90/Thy-1 Is Comparable in Hepatocellular Carcinoma of Eastern and Western Populations
An B. Luong, Huy Q. Do, Paola Tarchi, Deborah Bonazza, Cristina Bottin, Loraine Kay D. Cabral, Long D. C. Tran, Thao P. T. Doan, Lory S. Crocè, Hoa L. T. Pham, Claudio Tiribelli, Caecilia H. C. Sukowati
Cells.2020; 9(12): 2672. CrossRef - Histological architectural classification determines recurrence pattern and prognosis after curative hepatectomy in patients with hepatocellular carcinoma
Hirohisa Okabe, Tomoharu Yoshizumi, Yo-ichi Yamashita, Katsunori Imai, Hiromitsu Hayashi, Shigeki Nakagawa, Shinji Itoh, Norifumi Harimoto, Toru Ikegami, Hideaki Uchiyama, Toru Beppu, Shinichi Aishima, Ken Shirabe, Hideo Baba, Yoshihiko Maehara, Motoyuki
PLOS ONE.2018; 13(9): e0203856. CrossRef - Overexpression of epithelial cell adhesion molecule as a predictor of poor outcome in patients with hepatocellular carcinoma
Chih‑Jan Ko, Chia‑Jung Li, Meng‑Yu Wu, Pei‑Yi Chu
Experimental and Therapeutic Medicine.2018;[Epub] CrossRef - Clinicopathologic Significance of Survivin Expression in Relation to CD133 Expression in Surgically Resected Stage II or III Colorectal Cancer
Wanlu Li, Mi-Ra Lee, EunHee Choi, Mee-Yon Cho
Journal of Pathology and Translational Medicine.2017; 51(1): 17. CrossRef - PIN1 in hepatocellular carcinoma is associated with TP53 gene status
Jun Sang Bae, Sang Jae Noh, Kyoung Min Kim, Kyu Yun Jang, Ho Sung Park, Myoung Ja Chung, Byung-Hyun Park, Woo Sung Moon
Oncology Reports.2016; 36(4): 2405. CrossRef
- Nesidioblastosis and Pancreatic Non-functioning Islet Cell Tumor in an Adult with Type 2 Diabetes Mellitus
-
Ji Eun Choi, Sang Jae Noh, Jong Jin Sung, Woo Sung Moon
-
Korean J Pathol. 2013;47(5):489-491. Published online October 25, 2013
-
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.5.489
-
-
8,297
View
-
68
Download
-
9
Crossref
-
PDF
-
Citations
Citations to this article as recorded by - Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS): Review of the Literature of a Rare Cause of Hyperinsulinemic Hypoglycemia
Martin Philipp Dieterle, Ayman Husari, Sophie Nicole Prozmann, Hendrik Wiethoff, Albrecht Stenzinger, Manuel Röhrich, Uwe Pfeiffer, Wolfgang Rüdiger Kießling, Helena Engel, Harald Sourij, Thorsten Steinberg, Pascal Tomakidi, Stefan Kopf, Julia Szendroedi
Biomedicines.2023; 11(6): 1732. CrossRef - Postprandial hypoglycemia after upper gastrointestinal tract surgery: prevalence and pathophysiology (part 1)
M. Yu. Yukina, M. O. Chernova, E. A. Troshina, V. V. Evdoshenko, N. M. Platonova
Almanac of Clinical Medicine.2021; 49(4): 285. CrossRef - Nésidioblastose traitée par pasiréotide LAR : à propos d’un cas
Alexia Rouland, Benjamin Bouillet, Pauline Legris, Isabelle Simoneau, Jean-Michel Petit, Bruno Vergès
Médecine des Maladies Métaboliques.2021; 15(6): 619. CrossRef - Concurrent Adult-Onset Diffuse β-Cell Nesidioblastosis and Pancreatic Neuroendocrine Tumor: A Case Report and Review of the Literature
Mushfig Orujov, Keith K. Lai, Catherine L. Forse
International Journal of Surgical Pathology.2019; 27(8): 912. CrossRef - Nesidioblastosis in an Adult with Short Gut Syndrome and Type 2 Diabetes
Mimi Wong, Luke Conway, Caroline Cooper, Ashim Sinha, Nirjhar Nandi
AACE Clinical Case Reports.2019; 5(6): e375. CrossRef - Superimposed effect of ovariectomy on type 2 diabetes mellitus in Wistar rats
Minerva K. Fahmy, Hayam G. Sayyed, Eman A. Abd Elrahim, Rana T.A. Farag
Alexandria Journal of Medicine.2018; 54(2): 129. CrossRef - Diagnostic Performance of 48-Hour Fasting Test and Insulin Surrogates in Patients With Suspected Insulinoma
Keijiro Ueda, Ken Kawabe, Lingaku Lee, Yuichi Tachibana, Nao Fujimori, Hisato Igarashi, Yoshinao Oda, Robert T. Jensen, Ryoichi Takayanagi, Tetsuhide Ito
Pancreas.2017; 46(4): 476. CrossRef - Nesidioblastosis (diagnosis, surgical treatment)
A. G. Kriger, A. V. Smirnov, D. V. Kalinin, A. V. Glotov, S. V. Berelavichus, G. I. Konyaeva, A. N. Lebedeva, N. A. Karel’skaya, V. N. Tsygankov
Khirurgiya. Zhurnal im. N.I. Pirogova.2015; (10): 16. CrossRef - A Rare Complication of Gastric Bypass (Weight Loss) Surgery
Betül Ünal, Özlem Ceren Uzun, Cumhur İbrahim Başsorgun, Okan Erdoğan, Gülsüm Özlem Elpek
International Journal of Surgical Pathology.2015; 23(1): 68. CrossRef
|
E-submission
